Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P629: Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one yearECCO '17 Barcelona
Year: 2017
Authors:

Rodríguez Glez G.E.*1, Díaz Hernández L.1, Morales Barrios J.A.2, Vela González M.1, Tardillo Marín C.A.1, Viña Romero M.M.2, Rodríguez Díaz C.Y.1, Arranz Hernández L.1, Hernández Camba A.1, Merino Alonso F.J.2, Pérez Hernández F.1

1Hospital Universitario Ntra. Sra. Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain 2Hospital Universitario Ntra. Sra. Candelaria, Pharmacology, Santa Cruz de Tenerife, Spain

P630: The long-term efficacy of adalimumab on Crohn's disease comorbid with perianal lesions and poor prognostic factor analysisECCO '17 Barcelona
Year: 2017
Authors:

Nozaki R., Goto H., Tsuji Y., Takano S., Yamada K., Takano M.

Coloproctology Center, Takano Hospital, Kumamoto, Japan

P631: Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in inflammatory bowel diseasesECCO '17 Barcelona
Year: 2017
Authors:

Bibani N., Yakoubi M., Sabbah M., Trad D., Ouakaa A., Gargouri D., Elloumi H., Kharrat J.

Habib Thameur Hospital, Gastro enterology, Tunis, Tunisia

P632: Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Juan G.*1, Mora M.2, Alvariño A.3, Maroto N.2, Ferrer I.2, Hinojosa E.2, Hinojosa M.D.2, Ferrandis P.1, Hinojosa J.2

1Hospital de Manises, Department of Pharmacy, Manises, Spain 2Hospital de Manises, IBD Unit, Manises, Spain 3Hospital de Manises, Department of Labratory, Manises, Spain

P633: Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Fiorino G.*1, Ruiz-Agüello M.B.2, Maguregui A.2, Nagore D.2, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Martínez A.2, Danese S.1,3

1Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy 2Progenika Biopharma SA, R&D Department, Derio, Spain 3Humanitas University, Department of Biomedical Sciences, Milan, Italy

P634: Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

García Ortíz J.M., Sáenz Gallo M., Trigo Salado C., De La Cruz Ramirez M.D., Marquez Galan J.L., Herrera Justiniano J.M., Bozada García J.M., Leo Carnerero E.

HU Virgen del Rocío, UGC Digestive Diseases, Seville, Spain

P635: Enteral nutrition in the treatment of young adults with active Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Wall C.*1, Gearry R.2, Day A.1

1University of Otago Christchurch, Department of Paediatrics, Christchurch, New Zealand 2University of Otago, Christchurch, Department of Medicine, Christchurch, New Zealand

P636: Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapyECCO '17 Barcelona